ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2022

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera

Xiaohong Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.